Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Short term Debt (2017 - 2023)

Historic Short term Debt for Capricor Therapeutics (CAPR) over the last 9 years, with Q2 2023 value amounting to $18628.0.

  • Capricor Therapeutics' Short term Debt fell 8021.14% to $18628.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $18628.0, marking a year-over-year decrease of 8021.14%. This contributed to the annual value of $89234.0 for FY2022, which is 8511.25% down from last year.
  • Capricor Therapeutics' Short term Debt amounted to $18628.0 in Q2 2023, which was down 8021.14% from $18716.0 recorded in Q1 2023.
  • Over the past 5 years, Capricor Therapeutics' Short term Debt peaked at $599388.0 during Q4 2021, and registered a low of $18628.0 during Q2 2023.
  • In the last 3 years, Capricor Therapeutics' Short term Debt had a median value of $89234.0 in 2022 and averaged $211300.7.
  • The largest annual percentage gain for Capricor Therapeutics' Short term Debt in the last 5 years was 8021.14% (2023), contrasted with its biggest fall of 9674.42% (2023).
  • Quarter analysis of 3 years shows Capricor Therapeutics' Short term Debt stood at $599388.0 in 2021, then crashed by 85.11% to $89234.0 in 2022, then plummeted by 79.12% to $18628.0 in 2023.
  • Its last three reported values are $18628.0 in Q2 2023, $18716.0 for Q1 2023, and $89234.0 during Q4 2022.